# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 03-27-2024 | 12-31-2023 | 10-K |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Gil Blum reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $6 price target.
Cantor Fitzgerald analyst Kristen Kluska reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and maintains $7 p...
Needham analyst Gil Blum maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and raises the price target from $5 to $6.
Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.04) per share. This is a 42.86 percent increase over losse...
Cantor Fitzgerald analyst Kristen Kluska reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and maintains $7 p...